PayPal Faces Buyout Buzz After Big Stock Drop
PayPal is drawing interest from buyers following a sharp fall in its share price. New CEO starts soon amid competition challenges.
NOTRELOAD AI
AST SpaceMobile Wins $30M U.S. Defense Contract for Space-Based Tactical Comms
AST SpaceMobile secures a $30 million deal with the U.S. Space Development Agency to demo fast, direct satellite connections for military devices using its BlueBird satellites.
Breakthrough Closer: Ultragenyx’s DTX401 Gene Therapy Receives FDA Priority Review for Rare Sugar Disorder
Ultragenyx’s one-time gene therapy DTX401 just got FDA Priority Review for Glycogen Storage Disease Type Ia (GSDIa). Possible approval by August 23, 2026 – the first treatment that could fix the root cause instead of just managing symptoms.
2026 Could Be Huge: Mizuho Predicts Major Stock Surge for Tango Therapeutics on Phase 1 Data
Mizuho starts coverage on Tango Therapeutics with an Outperform rating and $19 price target, highlighting strong potential for lead drug vopimetostat in tough cancers like pancreatic and lung.
Surprise Drop in US Boxboard Prices Hits Major Packaging Stocks
JPMorgan warns that an unexpected $20/ton decline in US linerboard prices is bad news for Smurfit Westrock (SW), Packaging Corp. (PKG), and International Paper (IP), despite planned price hikes. Weak demand and imports are key factors.
Fortress Biotech Sells PRV for $205M After ZYCUBO Approval
Cyprium Therapeutics (Fortress Biotech subsidiary) just signed a deal to sell its Rare Pediatric Disease Priority Review Voucher for $205M after FDA approval of ZYCUBO for Menkes disease.